葡萄膜炎治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球葡萄膜炎治疗市场规模达7.685亿美元，预计到2034年将以6.6%的复合年增长率成长，达到15亿美元。这一增长主要源自于狼疮、克隆氏症和类风湿性关节炎等自体免疫疾病发生率的上升，这些疾病导致葡萄膜炎（尤其是非感染性葡萄膜炎）的盛行率上升。葡萄膜炎是一种影响葡萄膜（即眼球中层）的发炎性疾病，可能由感染、免疫系统疾病或发炎性疾病引起。它可能影响单眼或双眼，如果治疗不当，可能导致白内障、青光眼等严重併发症，甚至永久性视力丧失。

治疗葡萄膜炎包括控制发炎和预防长期眼部损伤。由于病情严重程度和病因差异很大，治疗方案必须因地制宜。市场对能够立即缓解症状并长期控制的药物的需求激增。认知度的提高、诊断技术的进步以及标靶疗法的研发促进了市场扩张。尤其是，对自体免疫疾病如何引发眼部发炎的理解日益加深，带来了更专业、更有效的治疗方案。治疗方案的创新——例如可减少全身性副作用的局部治疗——也日益受到关注。这种将症状缓解和潜在疾病控制相结合的综合方法，正在帮助医疗保健提供者提供更优质的医疗服务，同时支持市场的成长势头。

按治疗类型分类，皮质类固醇在2024年占据了最大的收入份额，占市场份额的37.3%。这些药物能够高效快速地消炎，使其成为许多急性和慢性葡萄膜炎患者的第一线治疗药物。它们有多种剂型，包括外用、口服和注射，方便医护人员根据患者病情和反应调整治疗方案。在慢性病例中持续使用皮质类固醇可确保持续的需求，并增强其在预防眼压升高和视神经损伤等併发症方面的作用。

就疾病类型而言，前葡萄膜炎占主导地位，2024 年收入达 4.246 亿美元。它是最常见的诊断类型，占所有葡萄膜炎病例的 40% 至 50%。鑑于其在年轻人中的普遍性，对不仅包含皮质类固醇，还包含免疫抑制剂和非类固醇抗发炎药 (NSAID) 的治疗方案的需求巨大。能够根据病情严重程度和患者需求透过多种途径给药，有助于改善疗效并推动市场成长。越来越多的医生选择标靶治疗来减少疾病发作并预防復发。

根据给药方式，局部用药在2024年以4.137亿美元的收入领先市场。含有皮质类固醇和非类固醇抗发炎药的眼药水因其针对性作用而被广泛使用，有助于最大限度地减少口服或註射药物相关的全身性副作用。其成本效益也发挥关键作用，尤其是在医疗预算有限的地区。局部用药製剂更容易使用，患者也更容易取得，这有助于更好地遵守治疗方案。

从病因来看，非感染性葡萄膜炎占市场主导地位，2024年营收达5.582亿美元。随着自体免疫疾病的增多，该细分市场持续扩张。许多此类疾病的眼部表现需要长期治疗。免疫抑制和生物疗法的最新进展使得更精准地靶向发炎的根本原因成为可能，从而提供更好的控制效果并减少不良反应。这些治疗在皮质类固醇疗效不足或导致严重副作用的情况下尤其重要。

在配销通路领域，医院药局以2024年3.291亿美元的收入领先市场。生物製剂和免疫抑制剂的使用日益增多，这些药物通常需要专业处理和密切监测，这提升了医院药房的角色。这些设施配备了管理复杂疗法、注射和监测患者潜在不良反应所需的基础设施。医院对药局服务的投入，为慢性或重度葡萄膜炎患者提供了更全面的照护。

光是美国市场就预计将大幅成长，预计到2034年市场总规模将达到6.122亿美元。监管支持，尤其是相关卫生部门及时批准新疗法，在确保患者获得尖端治疗方面发挥关键作用。随着主要参与者专注于创新（例如生物製剂、类固醇释放植入物和基因疗法），以改善治疗效果并占领更大的市场份额，市场竞争态势日益加剧。随着企业致力于整合现代技术、扩大全球影响力并满足日益增长的对有效且经济实惠的葡萄膜炎治疗的需求，与研究中心和医疗机构的合作也变得越来越普遍。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 葡萄膜炎及相关疾病的盛行率不断上升
    • 生物疗法的进展
    • 意识和医疗保健支出不断增长
  • 产业陷阱与挑战
    • 先进疗法成本高昂
    • 长期治疗的副作用
• 成长潜力分析
• 监管格局
• 技术格局
• 未来市场趋势
• 差距分析
• 专利分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依治疗类型，2021 年至 2034 年

• 主要趋势
• 皮质类固醇
• 免疫抑制剂/免疫调节剂
• 生物製剂
• 睫状肌麻痹剂
• 止痛药
• 其他治疗

第六章：市场估计与预测：依疾病类型，2021 年至 2034 年

• 主要趋势
• 前葡萄膜炎
• 后葡萄膜炎
• 中间葡萄膜炎
• 全葡萄膜炎

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 外用
• 注射剂

第 8 章：市场估计与预测：按疾病病因，2021 年至 2034 年

• 主要趋势
• 传染性
• 非传染性

第九章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务
• 其他分销管道

第十章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• AbbVie
• Alimera Sciences
• Bausch Health Companies
• Clearside Biomedical
• EyePoint Pharmaceuticals
• Novartis
• Pfizer
• Santen Pharmaceutical

The Global Uveitis Treatment Market was valued at USD 768.5 million in 2024 and is estimated to grow at a CAGR of 6.6% to reach USD 1.5 billion by 2034. This growth is fueled primarily by the increasing incidence of autoimmune disorders such as lupus, Crohn's disease, and rheumatoid arthritis, which contribute to a higher prevalence of uveitis-particularly the non-infectious types. Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, and may result from infections, immune system disorders, or inflammatory diseases. It can impact one or both eyes and, if not properly managed, may cause serious complications like cataracts, glaucoma, or even permanent vision loss.

Treating uveitis involves controlling inflammation and preventing long-term ocular damage. As the condition varies widely in severity and origin, therapies must be tailored accordingly. The market has seen a surge in demand for medications that offer both immediate relief and long-term management. Increased awareness, better diagnostics, and the development of targeted therapies have contributed to market expansion. In particular, the growing understanding of how autoimmune diseases trigger ocular inflammation has led to more specialized and effective treatment options. Innovations in treatment delivery-like localized therapies that reduce systemic side effects-are also gaining traction. This comprehensive approach, which incorporates both symptom relief and underlying disease control, is helping healthcare providers offer better care while supporting the market's upward trajectory.

When categorized by treatment type, corticosteroids commanded the largest revenue share in 2024, accounting for 37.3% of the market. These drugs are highly effective at rapidly reducing inflammation, making them a first-line treatment for many patients with both acute and chronic uveitis. They are available in multiple forms including topical, oral, and injectable, allowing healthcare professionals to adapt treatment plans based on the individual's condition and response. Continued use of corticosteroids in chronic cases ensures ongoing demand and reinforces their role in preventing complications like intraocular pressure increase and optic nerve damage.

In terms of disease type, anterior uveitis emerged as the dominant segment with revenue of USD 424.6 million in 2024. It is the most frequently diagnosed form, comprising 40% to 50% of all uveitis cases. Given its prevalence, especially in younger adults, there is significant demand for treatment options that include not only corticosteroids but also immunosuppressants and NSAIDs. The ability to administer these medications through various routes-depending on severity and patient needs-contributes to better outcomes and drives market growth. Physicians are increasingly choosing targeted therapies to reduce flare-ups and prevent recurrence.

Based on how the drugs are administered, topical treatments led the market with revenue of USD 413.7 million in 2024. Eye drops containing corticosteroids and NSAIDs are widely used due to their targeted action, which helps minimize systemic side effects associated with oral or injectable drugs. Their cost-effectiveness also plays a key role, particularly in regions with limited healthcare budgets. Topical formulations are easier to use and more accessible for patients, which encourages better adherence to treatment protocols.

Looking at disease etiology, non-infectious uveitis dominated the market with revenue reaching USD 558.2 million in 2024. This segment continues to expand in response to the rising number of autoimmune conditions. Many of these diseases have ocular manifestations that require long-term management. Recent advances in immunosuppressive and biologic therapies have made it possible to target the root cause of inflammation more precisely, offering better control with fewer adverse effects. These treatments are especially important in cases where corticosteroids are insufficient or lead to significant side effects.

In the distribution channel segment, hospital pharmacies led the market with USD 329.1 million in revenue in 2024. The increasing use of biologics and immunosuppressive agents-which often require specialized handling and close monitoring-has elevated the role of hospital pharmacies. These facilities are equipped with the infrastructure needed to manage complex therapies, administer injectables, and monitor patients for potential adverse reactions. Investments in pharmacy services across hospitals are enabling more comprehensive care for those living with chronic or severe uveitis.

The U.S. market alone is projected to grow substantially, with forecasts estimating a total market size of USD 612.2 million by 2034. Regulatory support, particularly the timely approval of new therapies by relevant health authorities, plays a pivotal role in ensuring patients gain access to cutting-edge treatments. Competitive dynamics within the market are intensifying as key players focus on innovation-such as biologic agents, steroid-releasing implants, and gene-based therapies-to improve therapeutic outcomes and capture a larger market share. Collaborations with research centers and healthcare institutions are becoming more common as companies work to integrate modern technologies, expand global reach, and meet the rising demand for effective, affordable uveitis treatments.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of uveitis and associated conditions
    • 3.2.1.2 Advancements in biologic therapies
    • 3.2.1.3 Growing awareness and healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of advanced therapies
    • 3.2.2.2 Side effects of long-term treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Patent analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Immunosuppressants/Immunomodulators
• 5.4 Biologics
• 5.5 Cycloplegic agents
• 5.6 Analgesics
• 5.7 Other treatments

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Anterior uveitis
• 6.3 Posterior uveitis
• 6.4 Intermediate uveitis
• 6.5 Panuveitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Disease Etiology, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Infectious
• 8.3 Non-infectious

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 E-commerce
• 9.5 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AbbVie
• 11.2 Alimera Sciences
• 11.3 Bausch Health Companies
• 11.4 Clearside Biomedical
• 11.5 EyePoint Pharmaceuticals
• 11.6 Novartis
• 11.7 Pfizer
• 11.8 Santen Pharmaceutical